Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 326

Similar articles for PubMed (Select 19385967)

1.

Cyclin E correlates with manganese superoxide dismutase expression and predicts survival in early breast cancer patients receiving adjuvant epirubicin-based chemotherapy.

Sgambato A, Camerini A, Collecchi P, Graziani C, Bevilacqua G, Capodanno A, Migaldi M, Masciullo V, Scambia G, Rossi G, Cittadini A, Amoroso D.

Cancer Sci. 2009 Jun;100(6):1026-33. doi: 10.1111/j.1349-7006.2009.01141.x. Epub 2009 Mar 31.

PMID:
19385967
2.

Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer.

Span PN, Tjan-Heijnen VC, Manders P, Beex LV, Sweep CG.

Oncogene. 2003 Jul 31;22(31):4898-904.

PMID:
12894232
3.

Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer.

Generali D, Fox SB, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield SM, Bruzzi P, Bersiga A, Allevi G, Milani M, Aguggini S, Dogliotti L, Bottini A, Harris AL.

Endocr Relat Cancer. 2006 Sep;13(3):921-30.

4.

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.

Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31.

PMID:
18668363
5.

Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy.

Mottolese M, Benevolo M, Del Monte G, Buglioni S, Papaldo P, Nisticò C, Di Filippo F, Vasselli S, Vici P, Botti C.

J Cancer Res Clin Oncol. 2000 Dec;126(12):722-9.

PMID:
11153146
6.

CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.

Brennan DJ, Jirstrom K, Kronblad A, Millikan RC, Landberg G, Duffy MJ, Rydén L, Gallagher WM, O'Brien SL.

Clin Cancer Res. 2006 Nov 1;12(21):6421-31.

7.

Prognostic relevance of cyclin E expression in operable breast cancer.

Potemski P, Kusińska R, Pasz-Walczak G, Piekarski JH, Watała C, Płuciennik E, Bednarek AK, Kordek R.

Med Sci Monit. 2009 Feb;15(2):MT34-40.

PMID:
19179977
8.

HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results.

Colozza M, Sidoni A, Mosconi AM, Cavaliere A, Bisagni G, Gori S, De Angelis V, Frassoldati A, Cherubini R, Bian AR, Rodino C, Mazzocchi B, Mihailova Z, Bucciarelli E, Tonato M; Italian Oncology Group for Clincal Research.

Clin Breast Cancer. 2005 Aug;6(3):253-9.

PMID:
16137437
9.

Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.

Tzaida O, Gogas H, Dafni U, Kyroudi A, Papaspyrou I, Kyriakou V, Malamou-Mitsi V, Alamani M, Skopa C, Kostopoulos I, Kastritis E, Pectasides D, Briasoulis E, Kalofonos HP, Aravantinos G, Fountzilas G, Arapantoni-Dadioti P.

Oncology. 2007;72(5-6):388-96. doi: 10.1159/000113148. Epub 2008 Jan 14.

PMID:
18187961
10.

Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.

Derin D, Eralp Y, Ozluk Y, Yavuz E, Guney N, Saip P, Igci A, Ozmen V, Kücücük S, Aslay I, Aydiner A, Topuz E.

Cancer Invest. 2008 Aug;26(7):671-9. doi: 10.1080/07357900801891628.

PMID:
18608215
11.

Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.

Tinari N, Lattanzio R, Natoli C, Cianchetti E, Angelucci D, Ricevuto E, Ficorella C, Marchetti P, Alberti S, Piantelli M, Iacobelli S.

Clin Cancer Res. 2006 Mar 1;12(5):1501-6.

12.

Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment.

Chappuis PO, Donato E, Goffin JR, Wong N, Bégin LR, Kapusta LR, Brunet JS, Porter P, Foulkes WD.

Ann Oncol. 2005 May;16(5):735-42. Epub 2005 Mar 31.

13.

Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC).

Holm NT, Abreo F, Johnson LW, Li BD, Chu QD.

Breast Cancer Res Treat. 2009 Jan;113(2):293-9. doi: 10.1007/s10549-008-9921-8. Epub 2008 Feb 13.

PMID:
18270814
15.

Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.

Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Grill R, Stierer M, Gnant MF, Filipits M; Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res. 2008 Mar 15;14(6):1767-74. doi: 10.1158/1078-0432.CCR-07-4122.

16.

Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.

Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.

J Clin Oncol. 2008 Mar 20;26(9):1404-10. doi: 10.1200/JCO.2007.10.6393.

17.

Correlation of TLK1B in elevation and recurrence in doxorubicin-treated breast cancer patients with high eIF4E overexpression.

Byrnes KW, DeBenedetti A, Holm NT, Luke J, Nunez J, Chu QD, Meschonat C, Abreo F, Johnson LW, Li BD.

J Am Coll Surg. 2007 May;204(5):925-33; discussion 933-4.

PMID:
17481512
18.

Aberrant expression of cyclin E in low-risk node negative breast cancer.

Ahlin C, Gruhne B, Holmqvist M, Zetterberg A, Fjällskog ML.

Acta Oncol. 2008;47(8):1539-45. doi: 10.1080/02841860701856581.

PMID:
18607847
19.

Concurrent chemoradiotherapy in adjuvant treatment of breast cancer.

Ismaili N, Mellas N, Masbah O, Elmajjaoui S, Arifi S, Bekkouch I, Ahid S, Bazid Z, Tazi MA, Erraki A, El Mesbahi O, Benjaafar N, El Gueddari Bel K, Ismaili M, Afqir S, Errihani H.

Radiat Oncol. 2009 Apr 7;4:12. doi: 10.1186/1748-717X-4-12.

20.

Efficacy of adjuvant chemotherapy according to Prion protein expression in patients with estrogen receptor-negative breast cancer.

Meslin F, Conforti R, Mazouni C, Morel N, Tomasic G, Drusch F, Yacoub M, Sabourin JC, Grassi J, Delaloge S, Mathieu MC, Chouaib S, Andre F, Mehrpour M.

Ann Oncol. 2007 Nov;18(11):1793-8. Epub 2007 Sep 14.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk